CC
OPNT

Claybrook Capital’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Claybrook Capital’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-50
Closed -$1K – 839
2018
Q3 		$1K Buy
+50
New +$866 ﹤0.01% 192

Other funds holding OPNT

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
BCM
Brasada Capital Management Houston, Texas $545M AUM 18.58% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Claybrook Capital's OPNT Position: Q4 2018 in Review

Claybrook Capital sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2018, closing a stake of 50 shares — an estimated $1K sold.

Claybrook Capital first reported a position in OPNT in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 23 funds tracked by Wall St. Rank hold OPNT as of Q4 2018.

  • Claybrook Capital reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Claybrook Capital sold 50 Opiant Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $1K.
  • Claybrook Capital first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Claybrook Capital's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $1K in Q3 2018.
  • 23 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Claybrook Capital's 13F filing for Q4 2018, filed 14 Feb 2019.